Effect of bacitracin on retroendocytosis and degradation of insulin in cultured kidney epithelial cell line

• Published in: Diabetes (New York, N.Y.) Vol. 39; no. 11; pp. 1339 - 1346
• Main Authors: Dahl, D C, Tsao, T, Duckworth, W C, Frank, B H, Rabkin, R
• Format: Journal Article
• Language: English
• Published: United States 01.11.1990
• Subjects: Animals; Bacitracin - pharmacology; Cell Line; Chromatography, High Pressure Liquid; Endocytosis - drug effects; Epithelial Cells; Epithelium - drug effects; Insulin - metabolism; Kidney - cytology; Kidney - drug effects; Opossums; Receptor, Insulin - drug effects; Receptor, Insulin - metabolism
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/diab.39.11.1339

In an earlier study, we described the presence of a retroendocytotic pathway for insulin in a cultured kidney epithelial cell line. Derived from the opossum kidney (OK), these cells possess many features of proximal tubule epithelium, which is the major site of kidney insulin metabolism. We studied the interaction between the retroendocytotic and the degradative pathways with bacitracin as a pharmacological probe. Monolayers of OK cells were loaded with 125I-labeled insulin over 30 min, acid washed to remove membrane-bound insulin, then incubated in fresh medium for 60 min while the release of intracellular radioactivity was monitored. In experiments carried out in the presence of bacitracin (2 mM), there was a two-thirds increase in intracellular radioactivity at the end of the loading phase. Measurements made during the subsequent release phase showed that bacitracin reduced the release of degradation products. Thus, although controls released 72.1 +/- 8.1% of the internalized radioactivity as trichloroacetic acid (TCA)-soluble products, bacitracin-treated cells released 59.2 +/- 9.4% (P less than 0.02). In contrast, release of TCA-precipitable insulin increased from 15.2 +/- 4.6% in controls to 25.8 +/- 3.7% in bacitracin-treated cells (P less than 0.01). In separate experiments analyzed by gel-exclusion chromatography, 6.4 +/- 0.6% of radioactivity released from preloaded control cells into medium over 60 min was insulin sized compared to 29.7 +/- 1.4% in bacitracin-treated cells. High-performance liquid chromatography revealed that 61.5 +/- 3.5% of this insulin-sized material released from control cells preloaded with A14-insulin eluted as intact insulin and the remainder as unidentified intermediate degradation products.